Tweak receptor agonists as anti-angiogenic agents
View Patent ↗The present invention relates to methods of modulating angiogenesis and inhibiting tumor progression by using TWEAK receptor (Fn14) agonists. In particular, methods for inhibiting angiogenesis are disclosed.
1. A method of inhibiting VEGF-dependent angiogenesis in a subject, who has a tumor, the method comprising administering to a subject a therapeutically effective amount of an anti-Fn14 agonist antibody that binds human Fn14 and augments Fn14 signaling.
2. The method of claim 1 , wherein the anti-Fn14 agonist antibody is a monoclonal antibody.
3. The method of claim 1 or 2 , wherein the antibody is a humanized antibody.
4. The method of claim 1 or 2 , wherein the antibody is a chimeric antibody.
5. The method of claim 1 or 2 , wherein the antibody is fully human.
6. The method of claim 1 or 2 , wherein the antibody is primatized.
7. The method of claim 1 or 2 , wherein the antibody is multivalent.
8. The method of claim 1 or 2 , wherein the antibody is an IgG.
9. The method of claim 1 or 2 , wherein the antibody is an IgM.
10. The method of claim 1 or 2 , wherein the antibody is administered at a dose of about 10–300 μg/kg body weight of the subject.
11. The method of claim 1 or 2 , wherein the antibody is administered via the parenteral, intravenous, subcutaneous, intraperitoneal or intracapsular route.
12. The method of claim 1 or 2 , wherein the antibody is administered in combination with radiation or chemotherapy.
13. A method of inhibiting VEGF-dependent angiogenesis, the method comprising administering, to a human subject who has a tumor, a therapeutically effective amount of a recombinant anti-Fn14 agonist IgG antibody that binds to human Fn14 and that augments Fn14 signaling, wherein the antibody is fully human or humanized.